| Opdivo (nivolumab) / BMS |
ACTRN12624000732583: Safety, Feasibility, and Dose Study of Aethlon Hemopurifier in Solid Tumor Patients on Pembrolizumab or Nivolumab Monotherapy. |
|
|
| Not yet recruiting | N/A | 18 | | | Aethlon Medical Australia PTY Ltd, Aethlon Medical Australia PTY Ltd | Cancer | | | | |
ACTRN12624000770561: Survival and Patterns of Care in the Era of Chemo-, Radio-, and Immuno-Oncology for Gastroesophageal Junction Cancers
|
|
|
| Not yet recruiting | N/A | 600 | | | Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre | Gastroesophageal adenocarcinomas, Gastroesophageal cancer, Gastric cancer, Gastric adenocarcinomas | | | | |
RPL-EAP-001, NCT06590480: An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma |
|
|
| Available | N/A | | NA | RP1, vusolimogene oderparepvec, Nivolumab, Opdivo | Replimune Inc. | Advanced Melanoma | | | | |
jRCT1080224013: Special Drug Use-Results Survey of OPDIVO (classical Hodgkin's lymphoma) |
|
|
| Completed | N/A | 250 | Japan | Opdivo (nivolumab) - BMS | Ono Pharmaceutical Co., Ltd. | Classical Hodgkin's lymphoma | | | | |
CheckMate 218, NCT02186249: Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma |
|
|
| No Longer Available | N/A | | US, Canada | Nivolumab, Ipilimumab | Bristol-Myers Squibb | Malignant Melanoma | | | | |
|
| No Longer Available | N/A | | US, Canada, RoW | Nivolumab | Bristol-Myers Squibb | Stage III (Unresectable) or Stage IV Advanced Melanoma | 05/18 | 05/18 | | |
NCT06235164: The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer |
|
|
| Active, not recruiting | N/A | 585 | RoW | immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab | Fujian Medical University | Locally Advanced Gastric Cancer | 12/22 | 12/25 | | |
| Completed | N/A | 279 | RoW | Transarterial chemoembolization, TACE, Systemic treatment | Zhejiang University | Hepatocellular Carcinoma | 03/23 | 10/23 | | |
ChiCTR1800018615: Evaluation for efficacy and toxicity of Nivolumab monotherapy for advanced non-small cell lung cancer after first-line treatment failure based on second-generation sequencing and liquid chip platform |
|
|
| Recruiting | N/A | 60 | | PD1, TMB and serum cytokines was detected before nivolumab treatment. ;PD1, TMB and serum cytokines was detected before nivolumab treatment. | State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University, Free | Non-small cell lung cancer | | | | |
NCT05740501: Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer |
|
|
| Completed | N/A | 13 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Electronic Health Record Review, Questionnaire Administration | Mayo Clinic | Lung Non-Small Cell Carcinoma, Melanoma | 01/20 | 01/20 | | |
ChiCTR1900022077: Study for the correlation between the efficacy of navuzumab and immunity in patients with non-small cell lung cancer |
|
|
| Not yet recruiting | N/A | | | | Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Seqhealth Technology co. LTD | non-small cell lung cancer | | | | |
NCT06630429: A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors |
|
|
| Recruiting | N/A | 100 | US | Biospecimen Collection | Ohio State University Comprehensive Cancer Center | Non-Small Cell Lung Cancer, Renal Cell Carcinoma (RCC) | 12/25 | 12/25 | | |
CheckMate 169, NCT02475382: Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen |
|
|
| No Longer Available | N/A | | Canada, RoW | Nivolumab | Bristol-Myers Squibb | Squamous Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cancer | | | | |
ST-ICI, NCT03453892: Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition |
|
|
| Completed | N/A | 150 | Europe | Nivolumab, Pembrolizumab, Radiotherapy, Ipilimumab | University of Erlangen-Nürnberg Medical School | Metastatic Cancer | 02/21 | 12/22 | | |
| Recruiting | N/A | 500 | RoW | Chemotherapy, targeting therapy | The Affiliated Hospital of Qingdao University | Thoracic Cancer, Gynecologic Cancer, Abdomen Tumors, Malignant Melanoma | 06/21 | 06/23 | | |
NCT05942768: Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer |
|
|
| Completed | N/A | 103 | RoW | regorafenib plus anti-PD-1 antibodies, programmed cell death protein 1, immune checkpoint inhibitor | Hunan Cancer Hospital | Metastatic Colorectal Adenocarcinoma | 06/21 | 09/21 | | |
| Active, not recruiting | N/A | 40 | Europe | Nivolumab and Ipilimumab | ARCAGY/ GINECO GROUP, Bristol-Myers Squibb | Cervix Cancer | 08/21 | 08/24 | | |
ChiCTR1900025377: Combination of the Oncolytic Immunotherapy ONCORINE With the PD-1 Receptor Blocking Antibody Nivolumab in Patients With Advanced HCC Who Have Failed Prior Systemic Therapy |
|
|
| Not yet recruiting | N/A | 20 | | Oncolytic Immunotherapy ONCORINE combined with pd-1 antibody. | Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, BMS | HCC | | | | |
ChiCTR1800018149: A multicentre, open-label, randomised, controlled trial for the effect and safety of Afatinib with Nivolumab in the treatment of gallbladder carcinoma with ERBB2/3 mutation |
|
|
| Not yet recruiting | N/A | 522 | China | treating with Afatinib and Nivolumab ;treating with Afatinib ;treating with GEMOX | Xinhua Hospital affiliated to Shanghai Jiaotong University, School of Medicine ; Xinhua Hospital affiliated to Shanghai Jiaotong University, School of Medicine, Shanghai Hospital Development Center | gallbladder carcinoma | | | | |
ChiCTR1800019288: A clinical trial for safety and efficient of CD19CART cells combination with nivolumab in the treatment of refractory/relapsed B cell lymphoma |
|
|
| Recruiting | N/A | 50 | | CD19CART combined with anti-PD-1 antibody ;CD19CART | Tianjin First Central Hospital; Tianjin First Central Hospital, Self-raised | Relapse or refractory B-cells lymphoma | | | | |
| Active, not recruiting | N/A | 60 | Japan | Opdivo (nivolumab) - BMS | Kindai University Hospital | cancer | | | | |
CCGLC-009, NCT06194695: DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | N/A | 100 | RoW | drug eluting beads-transcatheter arterial chemoembolization, DEB-TACE, envatinib plus anti-PD(L)1 | Ze-yang Ding, MD, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer (CCGLC) | Cholangiocarcinoma Non-resectable | 12/24 | 06/25 | | |
IMNR, NCT06607809: Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC |
|
|
| Completed | N/A | 99 | RoW | | Dr. Lutfi Kirdar Kartal Training and Research Hospital | Metastatic Renal Cell Carcinoma | 01/23 | 01/24 | | |
NCT05170685: Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab |
|
|
| No Longer Available | N/A | | NA | Nivolumab plus Relatlimab FDC | Bristol-Myers Squibb | | | | | |
| Completed | N/A | 100 | Japan | Opdivo (nivolumab) - BMS | West Japan Oncology Group, ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb K.K. | Gastric Cancer | | | | |
| Completed | N/A | 826 | RoW | TACE+ICIs, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 05/22 | 02/23 | | |
NCT03200977: Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab |
|
|
| Active, not recruiting | N/A | 95 | US | Non-Interventional | Bristol-Myers Squibb | Lymphoma | 06/22 | 12/22 | | |
NCT03035890: Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer |
|
|
| Completed | N/A | 35 | US | Radiation, Hypofractionated Radiation, Immuno-Therapeutic Agent, Immunotherapy | West Virginia University, West Virginia Clinical and Translational Science Institute | Non Small Cell Lung Cancer Metastatic | 06/22 | 06/22 | | |
NCT06011330: Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer |
|
|
| Completed | N/A | 70 | RoW | Fruquintinib combined with anti-PD-1 antibodies, programmed cell death protein 1, immune checkpoint inhibitor | Hunan Cancer Hospital | Colorectal Cancer | 06/22 | 02/23 | | |
NCT06202781: Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy |
|
|
| Recruiting | N/A | 28 | RoW | SOX plus PD-1 inhibitor, Gastroscopic biopsy | Chinese PLA General Hospital | Gastric Cancer, Tumor Microenvironment, Immunotherapy, Chemotherapy | 06/24 | 07/24 | | |
NCT04639284: Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC |
|
|
| Recruiting | N/A | 200 | RoW | Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 07/22 | 07/23 | | |
ChiCTR2000037301: A Single Arm Prospective Trial of Combining CyberKnife Fractionated Radiosurgery and PD-1 Inhibitor Nivolumab in the Treatment of Limited Number (≤4) of Symptomatic Non-small-cell Lung Cancer Brain Metastases without Driver Mutations |
|
|
| Recruiting | N/A | 72 | | CyberKnife ;PD-L1 inhibitor | Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Shanghai Shenkang Hospital Development Center | lung cancer | | | | |
GASTO-1067, NCT04654234: Total-body PET/CT Imaging Using the uEXPLORER in Non-small Cell Lung Cancer Patients Treated by Induction Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiotherapy |
|
|
| Completed | N/A | 15 | RoW | Total body PET/CT (uExplorer) | Sun Yat-sen University | Non-small Cell Lung Cancer | 12/23 | 12/23 | | |
NCT04845139: A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma |
|
|
| Active, not recruiting | N/A | 1 | RoW | Nivolumab, NIVO；Opdivo; BMS-936558 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Refractory Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma, Primary Central Nervous System Lymphoma | 10/22 | 11/22 | | |
NCT06031376: Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC |
|
|
| Completed | N/A | 106 | RoW | Fruquintinib, PD-1 inhibitors, anti-PD-1 antibodies, Trifluridine/Tipiracil, TAS-102, Lonsurf, S 95005, Bevacizumab, Avastin | Hunan Cancer Hospital | Metastatic Colorectal Adenocarcinoma | 10/22 | 03/23 | | |
NCT04603248: A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma |
|
|
| Active, not recruiting | N/A | 50 | RoW | Nivolumab | Yonsei University | Head and Neck Squamous Cell Carcinoma (HNSCC) | 12/22 | 02/23 | | |
NCT05273827: Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium |
|
|
| Completed | N/A | 81 | RoW | neoadjuvant immunotherapy, anti-PD-1 therapy, Neoadjuvant chemotherapy, Cis-platinum combined with paclitaxel or pemetrexed | Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University General Hospital, Tianjin Chest Hospital | Immunotherapy, Analgesia, NSCLC, Delirium | 12/23 | 01/24 | | |
TAILOR, NCT04801966: Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study |
|
|
| Terminated | N/A | 3 | RoW | Trametinib, Cobimetinib, Binimetinib, Alpelisib, Vemurafenib, Dabrafenib, Encorafenib, Palbociclib, Olaparib, Ribociclib, Abemaciclib, Talazoparib, Nivolumab, Atezolizumab, Pembrolizumab | Peter MacCallum Cancer Centre, Australia | Cancer | 12/22 | 12/22 | | |
NCT04291755: Development and Analysis of a Stool Bank for Cancer Patients |
|
|
| Recruiting | N/A | 100 | US | Pembrolizumab Injection, nivolumab, ipilimumab, atlizumab | Persephone Biosciences, Pharm-Olam International | Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal | 12/28 | 12/28 | | |
| Recruiting | N/A | 50 | | Regorafenib combined with PD-1 monoclonal antibody and GM-CSF | Affiliated Hospital of Xuzhou Medical College; Affiliated Hospital of Xuzhou Medical College, Nil | advanced colorectal cancer (CRC) | | | | |
NCT05233358: HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure |
|
|
| Not yet recruiting | N/A | 176 | NA | Hepatic Artery Infusion Chemotherapy, HAIC, Transarterial Chemoembolization, TACE, Regorafenib, second-line target drug, Immune Checkpoint Inhibitors, Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, Toripalimab | The Central Hospital of Lishui City | Hepatocellular Carcinoma | 02/23 | 02/25 | | |
| Completed | N/A | 3102 | RoW | | Bristol-Myers Squibb | Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck | 02/23 | 02/23 | | |
NCT06196554: Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs |
|
|
| Recruiting | N/A | 40 | RoW | Oxaliplatin, Irinotecan (SN-38), 5-Fluorouracil, Paclitaxel, Pembrolizumab, Nivolumab | Dong Bing Zhao | Gastric Cancer, Organoid, Neoadjuvant Therapy | 06/24 | 06/24 | | |
NCT04490564: Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma |
|
|
| Active, not recruiting | N/A | 185 | Europe | PD-L1 Kit | Pharmassist Ltd, University of Athens | Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma | 05/23 | 06/23 | | |
| Recruiting | N/A | 30 | Europe | Immunological and tumour characterization | Centre Leon Berard | Renal Cancer Metastatic | 06/23 | 12/23 | | |
NCT03695952: A Prospective Cohort Study of Patients With Hepatobiliary Cancer Treated With Immune Checkpoint Inhibitors |
|
|
| Recruiting | N/A | 100 | RoW | Nivolumab or pembrolizumab, Immune checkpoint inhibitors | Asan Medical Center | Hepatocellular Carcinoma, Biliary Tract Cancer | 07/23 | 07/24 | | |
NCT05053295: Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer |
|
|
| Recruiting | N/A | 20 | RoW | autologous activated T lymphocyte, Immuncell-LC (Autologous activated T lymphocyte), | Gangnam Severance Hospital | Relapsed or Advanced Gastric Adenocarcinoma, Gastro-esophageal Junction Cancer | 07/23 | 09/23 | | |
CA209-1068, NCT06163170: A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma |
|
|
| Completed | N/A | 100 | US | Nivolumab +/- ipilimumab, Nivolumab | Bristol-Myers Squibb | Melanoma | 09/23 | 11/23 | | |
| Recruiting | N/A | 474 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 08/23 | | |
CHANCE2202, NCT05332496: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC |
|
|
| Recruiting | N/A | 220 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 09/23 | | |
EXIT, NCT05934214: EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database |
|
|
| Completed | N/A | 141630 | Europe | Immune checkpoint inhibitor | Groupe Hospitalier Pitie-Salpetriere, Institut Curie | Cancer, Immune-related Adverse Event, Immune Checkpoint Inhibitor-Related Myocarditis | 12/23 | 02/24 | | |
| Completed | N/A | 250 | Canada | Nivolumab | Bristol-Myers Squibb | Upper Gastrointestinal Cancer | 01/24 | 01/24 | | |
CA209-1443, NCT06361576: Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada |
|
|
| Completed | N/A | 700 | Canada | Nivolumab | Bristol-Myers Squibb | Upper Gastrointestinal Cancer | 01/24 | 01/24 | | |
FINN, NCT06487156: A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 400 | Europe | Nivolumab + ipilimumab | Bristol-Myers Squibb | Non-small Cell Lung Cancer (NSCLC) | 10/30 | 10/30 | | |
| Recruiting | N/A | 221 | Europe | Treatment with immune checkpoint inhibitors., Blood tests. | Hospital Universitario Araba, Hospital de Basurto, Hospital Donostia, Complejo Hospitalario de Navarra, Hospital Galdakao-Usansolo | Cancer, Metastatic Cancer, Solid Organ Cancer | 10/23 | 12/23 | | |
G/GEJ cancer, NCT06158919: A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer |
|
|
| Recruiting | N/A | 58 | RoW | Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine | Fudan University | Gastric Cancer/Adenocarcinoma of Esophagogastric Junction | 11/24 | 11/26 | | |
NENI, NCT06169956: An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany |
|
|
| Recruiting | N/A | 400 | Europe | Neoadjuvant nivolumab in combination with platinum-based chemotherapy | Bristol-Myers Squibb | Resectable Non-small Cell Lung Cancer | 09/30 | 09/30 | | |
ChiCTR2000040854: Immunotherapy efficacy predicted by plasma exosomes in patients with advanced non-small cell lung cancer (NSCLC) |
|
|
| Not yet recruiting | N/A | 200 | | patients who intend to receive anti PD-1 (pembrolizumab) therapy combined with chemotherapy as the first-line treatment ;patients who are going to receive second-line anti-PD-1 monotherapy (nivolumab) for progression after platinum based dual drug chemotherapy | Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, Research funding: Natural Science Foundation of Action Plan for Scientific and Technological Innovation (19ZR1410400). | non-small cell lung cancer | | | | |
IBFIC, NCT05260606: Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 100 | RoW | F-18 FDG PET/CT | Samsung Medical Center | Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors | 12/25 | 12/25 | | |
| Recruiting | N/A | 80 | Europe | 18F-PD-L1, tracer | The Netherlands Cancer Institute, Bristol-Myers Squibb | NSCLC Stage IV | 12/23 | 12/24 | | |
| Recruiting | N/A | 42 | US | Radiation Therapy, radiotherapy, RT, Cetuximab, Erbitux, Chemotherapy, Cisplatin, Immunotherapy, pembrolizumab, Keytruda, nivolumab, Opdivo, durvalumab, Imfinzi | Loren Mell, MD | Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma | 12/23 | 12/24 | | |
NCT04680598: Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study |
|
|
| Recruiting | N/A | 800 | RoW | ICI, Antiviral Prophylaxis | Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital, ZhongShan People 's Hospital | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
| Recruiting | N/A | 300 | RoW | TACE, transarterial chemoembolization, Lenvatinib, levima, Anti-PD-1 monoclonal antibody, PD-1 inhibitor, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, apatinib plus camrelizumab, Apa plus C, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga | Tongji Hospital, Chinese Cooperative Group of Liver Cancer, Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, The Second Affiliated Hospital of Fujian Medical University, Geneplus-Beijing Co. Ltd., Haplox Biotechnology Co., Ltd. | Hepatocellular Carcinoma Non-resectable | 12/23 | 12/24 | | |
REVOLUTION, NCT03891485: Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy |
|
|
| Recruiting | N/A | 200 | Europe | Immunological and tumour characterization | National Cancer Institute, Naples | RCC, Metastatic Renal Cell Carcinoma | 01/25 | 01/26 | | |
NCT05579847: Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy |
|
|
| Active, not recruiting | N/A | 20 | US | mHealth Smart Phone Application, eHEALS digital literacy test, Weekly Quiz, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire, Patient Post Intervention Survey | H. Lee Moffitt Cancer Center and Research Institute, Pfizer | Renal Cell Carcinoma Stage IV | 01/24 | 01/25 | | |
FL001, NCT05547282: Low-dose Radiotherapy Combined With Conventional Radiotherapy After Immunotherapy Failure |
|
|
| Recruiting | N/A | 20 | RoW | At the same time, the original regimen of immunomaintenance therapy was continued, according to the frequency of the original immunization regimen once every 3 weeks until progress. | Jiandong Zhang | Cancer Patients | 02/24 | 02/24 | | |
CA209-1275, NCT06345183: Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients |
|
|
| Active, not recruiting | N/A | 327 | US | Nivolumab + Ipilimumab combination therapy, Pembrolizumab + Lenvatinib combination therapy | Bristol-Myers Squibb | Advanced Renal Cell Carcinoma (aRCC) | 06/24 | 12/24 | | |
REPLICA, NCT04106349: Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC) |
|
|
| Recruiting | N/A | 150 | Europe | | Ipsen | Advanced or Metastatic Renal Cell Carcinoma | 12/24 | 06/26 | | |
CA209-1429, NCT06452329: A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer |
|
|
| Active, not recruiting | N/A | 260 | RoW | Nivolumab | Bristol-Myers Squibb | Gastric Cancer, Gastroesophageal Junction Cancer | 04/25 | 07/25 | | |
| Completed | N/A | 868 | Europe | | Bristol-Myers Squibb | Non-Small Cell Lung Cancer | 12/23 | 12/23 | | |
| Recruiting | N/A | 153 | Europe | various neoadjuvant therapies | IRCCS San Raffaele | Bladder Cancer | 03/26 | 03/27 | | |
NCT02847728: Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice |
|
|
| Completed | N/A | 1189 | Europe, US, RoW | | Bristol-Myers Squibb | Melanoma, Lung Cancer | 03/24 | 03/24 | | |
CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor | Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Non-resectable | 04/24 | 12/24 | | |
ChiCTR2100045525: Clinical study of TACE combined with immunotherapy in patients with intermediate and advanced hepatocellular carcinoma |
|
|
| Recruiting | N/A | 100 | China | Transcatheter arterial chemoembolization (TACE) ;TACE+Nivolumab Hepatic Artery Perfusion | Chinese PLA General Hospital ; Chinese PLA General Hospital, Self-financed | Hepatocellular carcinoma | | | | |
NCT04146064: Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response |
|
|
| Recruiting | N/A | 425 | Canada | Breathprint analysis and patient-reported outcomes | University Health Network, Toronto, University of Amsterdam | NSCLC, Melanoma, Kidney Cancer, Urothelial Carcinoma, Head and Neck Cancer | 05/24 | 05/24 | | |
| Active, not recruiting | N/A | 150 | RoW | PD-1 inhibitor based immunotherapy | Shanghai Pulmonary Hospital, Shanghai, China | Non-small Cell Lung Cancer | 01/24 | 01/25 | | |
NCT02833233: A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer |
|
|
| Completed | N/A | 5 | US | Cryoablation, Ipilimumab, Nivolumab | Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb | Breast Cancer | 06/24 | 06/24 | | |
NCT04465942: Immunotherapy in Lung Cancer: Treatment After IO Cessation. |
|
|
| Recruiting | N/A | 300 | Europe | (chemo)immunotherapy, cisplatinum, carboplatinum, pemetrexed, paclitaxel, pembrolizumab, nivolumab, atezolizumab | European Lung Cancer Working Party | Carcinoma, Non-Small-Cell Lung, Immunotherapy | 06/24 | 06/25 | | |
| Recruiting | N/A | 1220 | Europe | pembrolizumab plus axitinib, nivolumab plus cabozantinib, pembrolizumab plus lenvatinib, nivolumab plus ipilimumab, avelumab plus axitinib, atezolizumab plus bevacizumab | Hospital of Macerata | Metastatic Renal Cell Carcinoma (mRCC) | 06/24 | 12/24 | | |
ChiCTR2300072369: A prospective study on the effects of neoadjuvant immunotherapy combined with chemotherapy on oral microflora, intratumoral microflora and untargeted metabolites in non-small cell lung cancer(NSCLC) |
|
|
| Recruiting | N/A | 50 | China | Based on CheckMate-816 clinical research, the National Comprehensive Cancer Network (NCCN) guidelines added a neoadjuvant immunochemotherapy regimen: PD-1 inhibitor Opdivo (nivolumab) combined with platinum-containing double drug chemotherapy once every 3 weeks, followed by surgery after up to 3 cycles. Pemetrexel combined with platinum-based chemotherapy is recommended for adenocarcinoma based on the pathological type of non-small cell lung cancer. Chemotherapy for squamous cell carcinoma is docetaxel combined with platinum or gemcitabine combined with platinum. Other options include yew in combination with platinum. | The First Affiliated Hospital, Zhejiang University of Medicine ; The First Affiliated Hospital, Zhejiang University of Medicine, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Clinical Research Center for Oral Diseases of Zhejiang Province, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Dental Biomaterials and Devices of Zhejiang Province | lung cancer | | | | |
| Recruiting | N/A | 1800 | Europe | Nivolumab, Opdivo, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Durvalumab, Imfinzi, Tremelimumab, CP-675,206, Atezolizumab, Tecentriq, Bevacizumab, Avastin | CCTU- Cancer Theme, Microbiotica Ltd | Melanoma, Renal Cancer, Lung Cancer | 07/24 | 07/25 | | |
URADJ, NCT06421311: Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France |
|
|
| Recruiting | N/A | 300 | Europe | nivolumab | Bristol-Myers Squibb | Urothelial Carcinoma | 05/28 | 05/28 | | |
NCT03458455: Improved Therapy Response Assessment in Metastatic Brain Tumors |
|
|
| Active, not recruiting | N/A | 200 | Europe | Magnetic Resonance Imaging, Vessel Architectural Imaging, Stereotactic Radiosurgery, Ipilimumab, nivolumab or pembrolizumab, Immunotherapy | Oslo University Hospital, Hospital of Southern Norway Trust, Ostfold Hospital Trust, St. Olavs Hospital, Massachusetts General Hospital, Dana-Farber Cancer Institute, University Medical Center Groningen, University of Texas Southwestern Medical Center, South-Eastern Norway Regional Health Authority, Norwegian Cancer Society | Brain Metastases | 07/24 | 12/24 | | |
CA209-1245, NCT06519682: A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG) |
|
|
| Not yet recruiting | N/A | 20 | NA | Nivolumab, Radiation | Daniel Morgenstern | High Grade Glioma, Replication Repair Deficient | 08/26 | 08/29 | | |
EROS, NCT06532149: ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer |
|
|
| Recruiting | N/A | 80 | Europe | Alectinib, Alecensa, Brigatinib, ALUNBRIG, Lorlatinib 100 mg, LORVIQUA, Osimertinib, Sotorasib, Dabrafenib, Trametinib, Selpercatinib, Pembrolizumab, Cemiplimab, Nivolumab, Carboplatin, Pemetrexed, Paclitaxel | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | NSCLC Stage IV, Sex Disorder, Hypogonadism, Male, Erectile Dysfunction | 09/26 | 09/26 | | |
NCT06428422: The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients |
|
|
| Recruiting | N/A | 100 | RoW | Bifidobacterium animalis subsp. lactis Bl-04, Plasebo | Necmettin Erbakan University, Health Institutes of Türkiye (TUSEB) | Metastatic Non-small Cell Lung Cancer | 10/25 | 12/26 | | |
CA209-7CR, NCT04043975: A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan |
|
|
| Active, not recruiting | N/A | 286 | Japan | | Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd | Advanced or Metastatic Renal Cell Carcinoma | 08/24 | 08/24 | | |
METAGIO, NCT06504615: Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France |
|
|
| Not yet recruiting | N/A | 500 | Europe | nivolumab + chemotherapy | Bristol-Myers Squibb | Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC) | 08/28 | 08/28 | | |
| Active, not recruiting | N/A | 502 | Europe | Nivolumab | Bristol-Myers Squibb | Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck | 09/24 | 09/24 | | |
| Not yet recruiting | N/A | 160 | Europe | Immunotherapy, pembrolizumab, nivolumab, ipilimumab | University Hospital, Montpellier | Melanoma, Immunotoxicity | 12/26 | 06/27 | | |
Vigilant-2, NCT06675643: Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity: A Feasibility Study of the Vigilant App |
|
|
| Recruiting | N/A | 30 | US | Non-Interventional Study | Mayo Clinic | Malignant Skin Neoplasm, Melanoma | 10/25 | 10/25 | | |
CA209-1428, NCT06499298: Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer |
|
|
| Not yet recruiting | N/A | 115 | RoW | Nivolumab | Bristol-Myers Squibb | Esophageal Cancer, Gastroesophageal Junction Cancer | 05/25 | 06/25 | | |
NCT06599619: Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi |
|
|
| Recruiting | N/A | 30 | US | Nivolumab, OPDIVO®, Pembrolizumab, Keytruda | John Kirkwood, Melanoma Research Foundation | Melanoma | 12/25 | 12/25 | | |
KETOREIN, NCT05119010: A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma |
|
|
| Recruiting | N/A | 60 | Europe | Continuous ketogenic diet, Discontinuous ketogenic diet, beta-hydroxybutyrate (BHB) supplementation | Gustave Roussy, Cancer Campus, Grand Paris | Metastatic Renal Cell Carcinoma | 11/24 | 11/24 | | |
NCT04161781: A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer |
|
|
| Completed | N/A | 10 | US | 18F-BMS-986229 Injection, IV 18F-BMS-986229, PET/CT Scan | Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb | Esophagogastric Cancer, Esophagus Cancer, Esophageal Cancer, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma | 03/24 | 03/24 | | |
I-STOP, NCT05418660: Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC |
|
|
| Recruiting | N/A | 300 | Europe | Immunotherapy, Nivolumab, Pembrolizumab, Atezolizumab | University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza | Non-small Cell Lung Cancer | 11/24 | 11/24 | | |
PRINCESS, NCT05821751: The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors |
|
|
| Recruiting | N/A | 40 | Europe | inulin, Pembrolizumab, Nivolumab | Fondazione del Piemonte per l'Oncologia, Ospedale Santa Croce-Carle Cuneo, Università degli Studi di Trento | Head and Neck Squamous Cell Carcinoma | 12/24 | 12/25 | | |
JOCARDITE, NCT04294771: JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors |
|
|
| Recruiting | N/A | 500000 | Europe | ICI, Immune checkpoint inhibitors | Groupe Hospitalier Pitie-Salpetriere | Myocarditis, Cardiomyopathies, Heart Diseases, Cardiovascular Diseases, Pericarditis, Vasculitis | 01/25 | 01/25 | | |
NCT06283238: Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON) |
|
|
| Not yet recruiting | N/A | 500 | US | Immune checkpoint inhibitor (ICI) or chemotherapy alone | Duke University | GastroEsophageal Cancer | 03/26 | 03/27 | | |
DELINOR, NCT05834348: A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. |
|
|
| Completed | N/A | 1 | Europe | lorlatinib, crizotinib, brigatinib, ceritinib, alectinib, atezolizumab, bevacizumab, paclitaxel, carboplatin, docetaxel, erlotinib, gefitinib, afatinib, dacomitinib, osimertinib, pembrolizumab, nivolumab, entrectinib | Pfizer | Non-Small Cell Lung Cancer | 01/24 | 01/24 | | |
